Clinical Trial Update: Switching From Intravenous to Subcutaneous Infliximab in Adult Patients With Inflammatory Bowel Disease [NA]

View source ↗

Summary

A completed clinical trial evaluated switching adult inflammatory bowel disease patients from intravenous to subcutaneous infliximab.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease
• Inflammatory Bowel Disease
• Ulcerative Colitis

Drugs mentioned

• Remicade (infliximab)

Snippet

Sponsor: Zuyderland Medisch Centrum | Conditions: IBD, Infliximab | NA | Status: COMPLETED